Kymera Therapeutics (NASDAQ:KYMR) COO Sells $349,080.82 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 4,279 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $81.58, for a total transaction of $349,080.82. Following the transaction, the chief operating officer directly owned 44,018 shares in the company, valued at approximately $3,590,988.44. This trade represents a 8.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Price Performance

KYMR stock traded up $0.93 during midday trading on Wednesday, reaching $81.70. 330,315 shares of the company’s stock traded hands, compared to its average volume of 667,424. The company has a market capitalization of $6.72 billion, a P/E ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $103.00. The business has a 50-day moving average price of $83.24 and a two-hundred day moving average price of $78.99.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.82) earnings per share. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on KYMR shares. Stephens lifted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Canaccord Genuity Group started coverage on shares of Kymera Therapeutics in a research note on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price target for the company. UBS Group lifted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Barclays lifted their price target on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 27th. Finally, Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $118.10.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP raised its holdings in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares during the period. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares during the period. Finally, State Street Corp raised its holdings in shares of Kymera Therapeutics by 9.4% during the fourth quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.